Oncotarget

Reviews:

Apatinib as targeted therapy for sarcoma

Feng Li, Zhichao Liao, Chao Zhang, Jun Zhao, Ruwei Xing, Sheng Teng, Jin Zhang, Yun Yang and Jilong Yang _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2018; 9:24548-24560. https://doi.org/10.18632/oncotarget.24647

Metrics: PDF 1571 views  |   HTML 2035 views  |   ?  


Abstract

Feng Li1,2,3,4, Zhichao Liao1,2,3,4, Chao Zhang1,2,3,4, Jun Zhao1,2,3,4, Ruwei Xing1,2,3,4, Sheng Teng1,2,3,4, Jin Zhang1,2,3,4, Yun Yang1,2,3,4 and Jilong Yang1,2,3,4

1Department of Bone and Soft Tissue Tumor, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China

2National Clinical Research Center of Cancer, Tianjin Medical University Cancer Institute & Hospital, Tianjin 300060, People’s Republic of China

3Key Laboratory of Cancer Prevention and Therapy, Tianjin 300060, People’s Republic of China

4Tianjin’s Clinical Research Center for Cancer, Tianjin 300060, People’s Republic of China

Correspondence to:

Jilong Yang, email: yangjilong@tjmuch.com

Keywords: apatinib; sarcoma; targeted therapy; efficacy; safety

Received: December 13, 2017    Accepted: February 25, 2018    Published: May 11, 2018

ABSTRACT

Sarcomas are a group of malignant tumors originating from mesenchymal tissue with a variety of cell subtypes. Despite several major treatment breakthroughs, standard treatment using surgery, radiation, and chemotherapy has failed to improve overall survival. Therefore, there is an urgent need to explore new strategies and innovative therapies to further improve the survival rates of patients with sarcomas. Pathological angiogenesis has an important role in the growth and metastasis of tumors. Vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptors (VEGFRs) play a central role in tumor angiogenesis and represent potential targets for anticancer therapy. As a novel targeted therapy, especially with regard to angiogenesis, apatinib is a new type of small molecule tyrosine kinase inhibitor that selectively targets VEGFR-2 and has shown encouraging anticancer activity in a wide range of malignancies, including gastric cancer, non-small cell lung cancer, breast cancer, hepatocellular carcinoma, and sarcomas. In this review, we summarize the preclinical and clinical data for apatinib, focusing primarily on its use in the treatment of sarcomas.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 24647